[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beone Medicines Ltd (ONC)

Beone Medicines Ltd (ONC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,640,858
  • Shares Outstanding, K 109,720
  • Annual Sales, $ 5,343 M
  • Annual Income, $ 286,930 K
  • EBIT $ 686 M
  • EBITDA $ 828 M
  • 60-Month Beta 0.49
  • Price/Sales 5.39
  • Price/Cash Flow 69.12
  • Price/Book 6.23

Options Overview Details

View History
  • Implied Volatility 39.23% (-1.23%)
  • Historical Volatility 30.44%
  • IV Percentile 4%
  • IV Rank 5.97%
  • IV High 56.45% on 11/05/25
  • IV Low 38.14% on 01/16/26
  • Expected Move (DTE 26) 24.04 (8.90%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 68
  • Volume Avg (30-Day) 48
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 1,932
  • Open Int (30-Day) 1,727
  • Expected Range 246.11 to 294.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.08
  • Number of Estimates 1
  • High Estimate $1.08
  • Low Estimate $1.08
  • Prior Year $0.84
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
253.95 +6.38%
on 06/11/26
312.01 -13.42%
on 05/26/26
-22.94 (-7.83%)
since 05/18/26
3-Month
253.95 +6.38%
on 06/11/26
328.39 -17.74%
on 04/17/26
-12.14 (-4.30%)
since 03/18/26
52-Week
239.25 +12.92%
on 07/02/25
385.22 -29.87%
on 11/17/25
+17.37 (+6.87%)
since 06/18/25

Most Recent Stories

More News
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment ...

ONC : 270.15 (+2.84%)
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk features New European patient research...

ONC : 270.15 (+2.84%)
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

BeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company said...

ONC : 270.15 (+2.84%)
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development Company to...

ONC : 270.15 (+2.84%)
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy ...

ONC : 270.15 (+2.84%)
3 Gold-Medal Mutual Funds to Buy Now

These mutual funds are the crème de la crème of their respective investment categories.

NVDA : 210.69 (+2.95%)
GOOGL : 368.03 (+1.17%)
ONC : 270.15 (+2.84%)
TDVG : 48.59 (+0.25%)
RYTM : 96.79 (+1.00%)
MU : 1,133.99 (+8.70%)
DODIX : 12.80 (+0.23%)
V : 327.24 (-0.95%)
ROST : 232.80 (-0.19%)
PRDGX : 88.18 (+0.35%)
CB : 323.40 (-1.39%)
WMT : 117.18 (-0.80%)
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026

TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEA ...

ONC : 270.15 (+2.84%)
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026,...

ONC : 270.15 (+2.84%)
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatment Three oral presentations at ASCO highlight rapid acceleration of BeOne’s solid...

ONC : 270.15 (+2.84%)
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard

Campaign connects the preparation, precision, and grit that define great goalkeeping to the persistent scientific, clinical, and community efforts that drive progress in cancer care ...

ONC : 270.15 (+2.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BeOne Medicines is an oncology company which involved in discovering and developing treatments to cancer patients. BeOne Medicines, formerly known as BeiGene Ltd., is based in SAN CARLOS, Calif.

See More

Key Turning Points

3rd Resistance Point 284.32
2nd Resistance Point 279.44
1st Resistance Point 274.79
Last Price 270.15
1st Support Level 265.26
2nd Support Level 260.38
3rd Support Level 255.73

See More

52-Week High 385.22
Fibonacci 61.8% 329.46
Fibonacci 50% 312.23
Fibonacci 38.2% 295.01
Last Price 270.15
52-Week Low 239.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.